Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 [intedanib] Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates.

Trial Profile

Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 [intedanib] Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Nintedanib (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms WoO
  • Most Recent Events

    • 01 Sep 2016 Results predicting role of 18F-FMISO-PET (n=130) during window-of-opportunity phase published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 15 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 28 Jan 2014 Planned End Date changed from 1 Aug 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top